Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal J Meropol

Showing results (161-170 of 226) with videos related to

Pageof 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
Pancreas|March 12, 2016
Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic AdenocarcinomaEfrat Dotan, R Katherine Alpaugh, Karen Ruth, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 12, 2012
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancerAndre Konski, Tianyu Li, Michael Christensen, et al.
European Urology|August 1, 2019
Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial CancerEmily Feld, Joanna Harton, Neal J Meropol, et al.
Urology|January 3, 2016
Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based CohortJonathan E Kiechle, Robert Abouassaly, Cary P Gross, et al.
The Journal of Urology|June 23, 2015
Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal MassesWilliam Tabayoyong, Robert Abouassaly, Jonathan E Kiechle, et al.
Urology|June 19, 2016
Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based CohortElyn H Wang, James B Yu, Robert Abouassally, et al.
Clinical Colorectal Cancer|February 12, 2014
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancersCrystal S Denlinger, Neal J Meropol, Tianyu Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 3, 2014
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancerAndre Konski, Joshua E Meyer, Michael Joiner, et al.
Cancer Causes & Control : CCC|May 27, 2019
Development and validation of a model to predict outcomes of colon cancer surveillanceJohnie Rose, Laura Homa, Chung Yin Kong, et al.
Pageof 23

Showing results (161-170 of 226) with videos related to

Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1Anthony W Tolcher, Monica Mita, Neal J Meropol, et al.
Pancreas|March 12, 2016
Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic AdenocarcinomaEfrat Dotan, R Katherine Alpaugh, Karen Ruth, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 12, 2012
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancerAndre Konski, Tianyu Li, Michael Christensen, et al.
European Urology|August 1, 2019
Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial CancerEmily Feld, Joanna Harton, Neal J Meropol, et al.
Urology|January 3, 2016
Racial Disparities in Partial Nephrectomy Persist Across Hospital Types: Results From a Population-based CohortJonathan E Kiechle, Robert Abouassaly, Cary P Gross, et al.
The Journal of Urology|June 23, 2015
Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal MassesWilliam Tabayoyong, Robert Abouassaly, Jonathan E Kiechle, et al.
Urology|June 19, 2016
Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based CohortElyn H Wang, James B Yu, Robert Abouassally, et al.
Clinical Colorectal Cancer|February 12, 2014
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancersCrystal S Denlinger, Neal J Meropol, Tianyu Li, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 3, 2014
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancerAndre Konski, Joshua E Meyer, Michael Joiner, et al.
Cancer Causes & Control : CCC|May 27, 2019
Development and validation of a model to predict outcomes of colon cancer surveillanceJohnie Rose, Laura Homa, Chung Yin Kong, et al.
Pageof 23